Pieris Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2001-01-01
- Employees
- 50
- Market Cap
- $23.4M
- Website
- http://www.pieris.com
Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-01-13
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- Pieris Pharmaceuticals, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT05190445
- Locations
- 🇺🇸
Maryland Oncology-Hematology, Silver Spring, Maryland, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Sansum Clinic, Santa Barbara, California, United States
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Pieris Pharmaceuticals, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT03650348
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCLA Health, Santa Monica, California, United States
🇺🇸M.D. Anderson Cancer Center, Houston, Texas, United States
PRS-343 in HER2-Positive Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Pieris Pharmaceuticals, Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT03330561
- Locations
- 🇺🇸
Georgetown University, Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸University of Arizona Cancer Center, Tucson, Arizona, United States
© Copyright 2024. All Rights Reserved by MedPath